vTv Therapeutics, Inc.

As of May 15, 2025, vTv Therapeutics, Inc. is assessed as overvalued with a valuation grade of "does not qualify" due to poor financial metrics, including a price-to-book ratio of 6.58, negative EV to EBIT and EV to EBITDA ratios, and a return on equity of -291.62%, significantly underperforming against the S&P 500.

As of May 23, 2025, the trend is mildly bullish due to positive monthly MACD and RSI signals, though caution is advised from bearish weekly indicators.

As of March 2022, the management team of vTv Therapeutics, Inc. includes Executive Chairman Ms. Robin Abrams and Board members Mr. Hersh Kozlov, Mr. Richard Nelson, Mr. John Fry, Mr. Noel Spiegel, and Dr. Howard Weiner.

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered small molecule drug candidates. It has a market cap of $50.23 million and reported a net profit loss of $6 million as of March 2025.

As of Jun 18, vTv Therapeutics, Inc. has a market capitalization of 50.23 million and reported net sales of 0.02 million with a net profit of -22.91 million over the last four quarters. Shareholder's funds are 12.20 million, and total assets amount to 38.27 million.